AU2022315058A1 - Compounds and compositions for the treatment of coronaviral related diseases - Google Patents

Compounds and compositions for the treatment of coronaviral related diseases Download PDF

Info

Publication number
AU2022315058A1
AU2022315058A1 AU2022315058A AU2022315058A AU2022315058A1 AU 2022315058 A1 AU2022315058 A1 AU 2022315058A1 AU 2022315058 A AU2022315058 A AU 2022315058A AU 2022315058 A AU2022315058 A AU 2022315058A AU 2022315058 A1 AU2022315058 A1 AU 2022315058A1
Authority
AU
Australia
Prior art keywords
isoquinolin
carbonitrile
oxoimidazolidine
substituted
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022315058A
Other languages
English (en)
Inventor
Denghui BAO
Fengfeng GUO
Matthew James HESSE
Viktor HORNAK
Sajan Joseph
Thomas Martin Kirrane Jr.
Haiyao LIN
Bo Liu
Yanan MIAO
Heinz Ernst Moser
Julien Papillon
Yang Qu
Lei Shi
Jun Yuan
Teng ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2022315058A1 publication Critical patent/AU2022315058A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022315058A 2021-07-22 2022-07-20 Compounds and compositions for the treatment of coronaviral related diseases Pending AU2022315058A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163224793P 2021-07-22 2021-07-22
US63/224,793 2021-07-22
US202163289009P 2021-12-13 2021-12-13
US63/289,009 2021-12-13
PCT/IB2022/056712 WO2023002409A1 (en) 2021-07-22 2022-07-20 Compounds and compositions for the treatment of coronaviral related diseases

Publications (1)

Publication Number Publication Date
AU2022315058A1 true AU2022315058A1 (en) 2024-02-08

Family

ID=82742919

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022315058A Pending AU2022315058A1 (en) 2021-07-22 2022-07-20 Compounds and compositions for the treatment of coronaviral related diseases

Country Status (11)

Country Link
US (1) US20250092016A1 (cg-RX-API-DMAC10.html)
EP (1) EP4373814A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024527424A (cg-RX-API-DMAC10.html)
KR (1) KR20240038996A (cg-RX-API-DMAC10.html)
AU (1) AU2022315058A1 (cg-RX-API-DMAC10.html)
CA (1) CA3226758A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024000986A (cg-RX-API-DMAC10.html)
PY (1) PY2261702A (cg-RX-API-DMAC10.html)
TW (1) TW202321210A (cg-RX-API-DMAC10.html)
UY (1) UY39863A (cg-RX-API-DMAC10.html)
WO (1) WO2023002409A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7559223B2 (ja) 2020-08-24 2024-10-01 ギリアード サイエンシーズ, インコーポレイテッド リン脂質化合物及びその使用
TWI925033B (zh) 2020-10-16 2026-05-11 美商基利科學股份有限公司 磷脂化合物及其用途
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
AU2023249953A1 (en) 2022-04-08 2024-10-24 Shionogi & Co., Ltd. Uracil derivative having viral growth inhibitory activity and pharmaceutical composition containing same
AU2023303408A1 (en) 2022-07-06 2024-12-19 Aligos Therapeutics, Inc. Anti-viral compounds
CR20250040A (es) 2022-08-05 2025-03-18 Gilead Sciences Inc Inhibidores de la proteasa principal de sars-cov2
WO2025125695A2 (en) * 2024-12-17 2025-06-19 Medchemica Consultancy Ltd Chemical compoundsid50000167790940 p. doc 2025-05-07 filing no.:19

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1200825B (de) * 1962-01-13 1965-09-16 Hoechst Ag Verfahren zur Herstellung von 3, 5-Dioxo-triazolidinen
PE20121048A1 (es) * 2009-06-26 2012-08-25 Novartis Ag Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17

Also Published As

Publication number Publication date
MX2024000986A (es) 2024-02-12
WO2023002409A1 (en) 2023-01-26
UY39863A (es) 2023-02-28
CA3226758A1 (en) 2023-01-26
US20250092016A1 (en) 2025-03-20
EP4373814A1 (en) 2024-05-29
PY2261702A (es) 2023-06-14
KR20240038996A (ko) 2024-03-26
TW202321210A (zh) 2023-06-01
JP2024527424A (ja) 2024-07-24

Similar Documents

Publication Publication Date Title
US20250092016A1 (en) Compounds and compositions for the treatment of coronaviral related diseases
AU2018221812B2 (en) Pyrrolo [1,2-b] pyridazine derivatives
JP7097373B2 (ja) キナーゼ阻害剤としてのアミノトリアゾロピリジン
JP7471348B2 (ja) ブルトン型チロシンキナーゼの阻害剤及びその使用方法
US10508113B2 (en) Inhibitors of tyrosine kinase 2 mediated signaling
CN104922128B (zh) 流感病毒复制抑制剂
TWI594997B (zh) 流感病毒複製之抑制劑
JP2018076287A (ja) キナーゼ阻害剤としてのアミノヘテロアリールベンズアミド
JP7222590B2 (ja) 3-アザビシクロ[3,1,1]ヘプタン誘導体及びこれを含む薬学的組成物
WO2022224223A1 (en) Compounds and compositions for the treatment of coronaviral related diseases
WO2016024185A1 (en) Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
RS58245B1 (sr) Kombinacija derivata pirolo[2,3-d]pirimidina sa jednim ili više dodatnih sredstava kao inhibitor janus kinaza (jak)
CA2917193A1 (en) Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators
IL300289A (en) Compounds, preparations and methods
CN104619702A (zh) Ccr2的稠合环戊基拮抗剂
JP2025508323A (ja) Cdk4/6キナーゼの阻害薬
TW201805277A (zh) 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
EP4126876A1 (en) Pyrrolidine-pyrazoles as pyruvate kinase activators
EA050666B1 (ru) Соединения и композиции для лечения заболеваний, связанных с коронавирусной инфекцией
CN117651699A (zh) 用于治疗冠状病毒相关疾病的化合物和组合物
HK40012561B (en) Heteroaryl compounds and their use as mer inhibitors
HK1243063B (en) Pyrrolo [2, 3-d] pyrimidine derivatives as inhibitors of janus-related kinases (jak)
HK1204322B (en) Inhibitors of influenza viruses replication
HK1169326B (en) Inhibitors of influenza viruses replication